Indivior Pharmaceuticals, Inc. (INDV) Stock Price & How to Invest
Last updated July 2026
Short answer
Indivior (Nasdaq: INDV) is a specialty pharmaceutical company focused on addiction and serious mental illness, best known for SUBLOCADE, its long-acting injectable for opioid use disorder. Investing in INDV is a concentrated bet on the continued adoption of SUBLOCADE and the broader medication-assisted opioid treatment market.
INDV stock price
As of 2026-07-24, Indivior Pharmaceuticals, Inc. (INDV) last closed at $40.53, up 136.4% over the past year. Over the past 52 weeks it has traded between $17.09 and $41.83.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Indivior Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Indivior Pharmaceuticals, Inc. (INDV) do?
Indivior is a specialty pharmaceutical company that develops and markets treatments for opioid use disorder (OUD) and related conditions. Its flagship product, SUBLOCADE, is a once-monthly long-acting injectable form of buprenorphine that has become the dominant long-acting injectable (LAI) for OUD in the United States, holding roughly a 76% share of that market. The company also sells the sublingual film SUBOXONE (now facing generic competition), the opioid overdose reversal agent OPVEE (nalmefene nasal spray), and PERSERIS for schizophrenia. Indivior historically listed in London but shifted its primary listing to the Nasdaq, and it trades under the ticker INDV.
The investment picture is defined by concentration and transition. SUBLOCADE now drives the large majority of growth, with Q1 2026 SUBLOCADE net revenue of roughly $232 million (up about 32% year over year) helping total net revenue reach roughly $317 million. Management raised full-year 2026 guidance to roughly $1.215 to $1.285 billion in net revenue and roughly $620 to $660 million in adjusted EBITDA, reflecting expanding margins. Against a market capitalization of roughly $4.8 billion, INDV is valued as a mid-cap pharma whose thesis hinges on SUBLOCADE sustaining growth while legacy film revenue erodes and litigation overhangs recede.
What's driving Indivior Pharmaceuticals, Inc. (INDV)?
1. SUBLOCADE market leadership and expansion
SUBLOCADE is the clear leader in long-acting injectable treatment for opioid use disorder, with roughly a 76% U.S. LAI share and over 500,000 patients prescribed since launch. Growth has been driven by dispense unit volume gains (around 20% in Q1 2026) plus favorable price and mix. Expansion into criminal justice settings, health systems, and organic net-new prescribers is the central driver of the thesis.
2. Margin expansion and cash generation
Record quarterly adjusted EBITDA of roughly $164 million in Q1 2026 (up about 112% year over year) pushed margins above 50%. As SUBLOCADE scales and the company trims lower-return pipeline spending, operating leverage is improving. Strong cash generation supports buybacks and gives management flexibility on capital allocation.
3. Portfolio breadth beyond the core product
OPVEE (nalmefene) addresses opioid overdose reversal, and PERSERIS targets schizophrenia, giving Indivior optionality beyond SUBLOCADE. The company has also pruned its pipeline, deciding not to advance INDV-6001 to Phase 3 and reworking its Alar Pharmaceuticals agreement. This focus is intended to concentrate resources on the highest-return assets.
4. Structural demand for addiction treatment
The U.S. opioid crisis and rising policy support for medication-assisted treatment create a durable underlying market. Reimbursement expansion, reduced stigma, and treatment access initiatives all widen the addressable patient base. This macro backdrop underpins the long-term case for SUBLOCADE and adjacent products.
What are the risks to Indivior Pharmaceuticals, Inc. (INDV)?
Indivior is highly concentrated in a single product, so any slowdown in SUBLOCADE adoption, pricing pressure, or competitive entry (for example from Alkermes VIVITROL or Camurus and Braeburn's BRIXADI) would weigh heavily on the whole company. Legacy SUBOXONE film revenue continues to erode as generics take share, and the company has a long history of antitrust and opioid-related litigation and settlements that can resurface as financial and reputational overhangs. Reliance on government and Medicaid channels exposes revenue to reimbursement and budget shifts. Pipeline setbacks, such as the decision to halt INDV-6001 Phase 3, show that non-core bets may not deliver. As a specialty pharma, it also faces regulatory, patent, and manufacturing risks common to the sector.
How is Indivior Pharmaceuticals, Inc. (INDV) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Indivior Pharmaceuticals, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$1.2B
- 2026 revenue guidance: ~$1.215B to $1.285B
- SUBLOCADE Q1 2026 net revenue: ~$232M (up ~32% YoY)
- Adjusted EBITDA (2026 guide): ~$620M to $660M
- Market cap: ~$4.8B
- Price / sales (approx): ~4x
Indivior trades as a profitable mid-cap specialty pharma, with a price-to-sales multiple around 4x on roughly $1.2 billion of trailing revenue. The valuation embeds expectations that SUBLOCADE keeps compounding and that margins stay above 50%. Because one product drives most revenue, the multiple is sensitive to any change in SUBLOCADE's growth trajectory.
Who competes with Indivior Pharmaceuticals, Inc. (INDV)?
Long-acting injectable OUD treatments
The most direct competition comes from other long-acting buprenorphine and OUD therapies, including Camurus and Braeburn's BRIXADI and Alkermes' VIVITROL (naltrexone). These products compete for the same physician and patient base that SUBLOCADE serves.
Generic buprenorphine and naloxone products
Generic versions of buprenorphine and naloxone film and tablets (the SUBOXONE franchise) pressure legacy revenue and offer lower-cost alternatives. Multiple generic manufacturers erode pricing and share on the older sublingual products.
Overdose reversal and CNS specialty pharma
In overdose reversal, OPVEE competes with naloxone products such as Emergent BioSolutions' NARCAN. More broadly, Indivior competes with other central nervous system and specialty pharma companies for prescriber attention and reimbursement in addiction and mental health.
How to invest in Indivior Pharmaceuticals, Inc. (INDV)
There are three common ways to get INDV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so INDV sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where INDV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Indivior Pharmaceuticals, Inc. (INDV)
INDV is essentially a single-product growth story: the investment picture rises and falls with SUBLOCADE's ability to keep expanding while patents and generics on legacy products fade.
More on Indivior Pharmaceuticals, Inc. (INDV)
Whether INDV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is INDV a buy?, and where the stock could go from here in the INDV stock forecast.
For income investors, whether INDV pays a dividend and how the payout looks is covered in does INDV pay a dividend?
Build a basket around INDV with Walnut
Use Indivior Pharmaceuticals, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Indivior do?
+
Indivior is a specialty pharmaceutical company focused on treating opioid use disorder and related conditions. Its main product is SUBLOCADE, a once-monthly long-acting injectable buprenorphine, and it also markets OPVEE, PERSERIS, and the legacy SUBOXONE film.
What exchange does INDV trade on?
+
Indivior trades under the ticker INDV on the Nasdaq. The company historically listed in London but moved its primary listing to the United States.
What is SUBLOCADE and why does it matter to INDV?
+
SUBLOCADE is Indivior's flagship once-monthly injectable for opioid use disorder. It holds roughly a 76% share of the U.S. long-acting injectable market and drives the majority of the company's growth, so it is central to the investment case.
How large is Indivior?
+
As of July 2026, Indivior has a market capitalization of roughly $4.8 billion. Trailing twelve-month revenue is around $1.2 billion, with 2026 guidance of roughly $1.215 to $1.285 billion.
Is Indivior profitable?
+
Yes. Indivior reported GAAP net income of roughly $89 million in Q1 2026 and record adjusted EBITDA of about $164 million, reflecting margins above 50% as SUBLOCADE scales.
Who are Indivior's main competitors?
+
Competitors include other long-acting OUD treatments such as BRIXADI (Camurus and Braeburn) and VIVITROL (Alkermes), generic buprenorphine and naloxone products, and overdose reversal agents like NARCAN. It also competes with other CNS specialty pharma companies.
What are the biggest risks with INDV?
+
The largest risks are heavy reliance on a single product (SUBLOCADE), erosion of legacy SUBOXONE film to generics, ongoing litigation and settlement history, competitive entrants, and exposure to government and Medicaid reimbursement decisions.
How should an investor think about INDV?
+
INDV is best understood as a concentrated bet on continued SUBLOCADE growth and margin expansion within the addiction-treatment market. The investment picture depends on whether SUBLOCADE can keep gaining patients while legacy revenue fades and litigation overhangs recede. Walnut is not an investment adviser, so treat this as descriptive context, not a recommendation.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Indivior Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.